Charles River Laboratories International Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Charles River Laboratories International ha aumentado sus beneficios a una tasa media anual de 11.8%, mientras que los beneficios de la industria de Life Sciences han experimentado un crecimiento de 11.7% anual. Los ingresos han ido creciendo a una tasa media de 10.5% al año. La rentabilidad financiera de Charles River Laboratories International es de 11.2%, y sus márgenes netos son de 10.2%.
Información clave
11.8%
Tasa de crecimiento de los beneficios
10.8%
Tasa de crecimiento del BPA
Crecimiento de la industria Life Sciences | 21.5% |
Tasa de crecimiento de los ingresos | 10.5% |
Rentabilidad financiera | 11.2% |
Margen neto | 10.2% |
Última actualización de beneficios | 28 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19Desglose de ingresos y gastos
Cómo gana y gasta dinero Charles River Laboratories International. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
28 Sep 24 | 4,061 | 413 | 719 | 0 |
29 Jun 24 | 4,078 | 432 | 706 | 0 |
30 Mar 24 | 4,112 | 439 | 739 | 0 |
30 Dec 23 | 4,129 | 475 | 736 | 0 |
30 Sep 23 | 4,216 | 475 | 752 | 0 |
01 Jul 23 | 4,178 | 484 | 756 | 0 |
01 Apr 23 | 4,092 | 496 | 685 | 0 |
31 Dec 22 | 3,976 | 486 | 655 | 0 |
24 Sep 22 | 3,781 | 436 | 585 | 0 |
25 Jun 22 | 3,688 | 443 | 549 | 0 |
26 Mar 22 | 3,630 | 422 | 578 | 0 |
25 Dec 21 | 3,540 | 391 | 578 | 0 |
25 Sep 21 | 3,426 | 397 | 582 | 0 |
26 Jun 21 | 3,273 | 396 | 566 | 0 |
27 Mar 21 | 3,041 | 375 | 528 | 0 |
26 Dec 20 | 2,924 | 364 | 523 | 0 |
26 Sep 20 | 2,824 | 301 | 501 | 0 |
27 Jun 20 | 2,749 | 271 | 502 | 0 |
28 Mar 20 | 2,724 | 248 | 520 | 0 |
28 Dec 19 | 2,621 | 252 | 488 | 0 |
28 Sep 19 | 2,532 | 231 | 493 | 0 |
29 Jun 19 | 2,449 | 219 | 473 | 0 |
30 Mar 19 | 2,377 | 227 | 456 | 0 |
29 Dec 18 | 2,266 | 225 | 436 | 0 |
29 Sep 18 | 2,143 | 135 | 419 | 0 |
30 Jun 18 | 2,022 | 128 | 401 | 0 |
31 Mar 18 | 1,906 | 129 | 377 | 0 |
30 Dec 17 | 1,858 | 123 | 367 | 0 |
30 Sep 17 | 1,846 | 198 | 370 | 0 |
01 Jul 17 | 1,807 | 183 | 363 | 0 |
01 Apr 17 | 1,772 | 164 | 357 | 0 |
31 Dec 16 | 1,681 | 154 | 343 | 0 |
24 Sep 16 | 1,568 | 143 | 325 | 0 |
25 Jun 16 | 1,492 | 143 | 309 | 0 |
26 Mar 16 | 1,398 | 156 | 288 | 0 |
26 Dec 15 | 1,363 | 150 | 279 | 0 |
26 Sep 15 | 1,339 | 146 | 277 | 0 |
27 Jun 15 | 1,317 | 140 | 276 | 0 |
28 Mar 15 | 1,319 | 127 | 274 | 0 |
27 Dec 14 | 1,298 | 128 | 258 | 0 |
27 Sep 14 | 1,257 | 120 | 248 | 0 |
28 Jun 14 | 1,222 | 119 | 236 | 0 |
29 Mar 14 | 1,174 | 111 | 226 | 0 |
28 Dec 13 | 1,166 | 104 | 226 | 0 |
Ingresos de calidad: CRL tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(10.2%) de CRL son inferiores a los del año pasado (11.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de CRL han crecido un 11.8% al año en los últimos 5 años.
Acelerando crecimiento: CRL ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: CRL tuvo un crecimiento negativo de los beneficios (-13.1%) durante el año pasado, lo que dificulta la comparación con la media de la industria Life Sciences (-4.7%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de CRL (11.2%) se considera baja.